Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

The prevalence of coronavirus disease 2019 (COVID19) has posed a great threat to people’s health worldwide, bringing a great challenges to the public healthcare systems. A recent study has confirmed that severe acute respiratory syndrome coronavirus 2 (SARSCoV2) uses severe acute respiratory syndrome coronavirus (SARSCoV) receptor angiotensinconverting enzyme 2 (ACE2) for host cell entry.1 ACE2 expression was previously found to correlate with susceptibility to SARSCoV infection in vitro.2 As with SARSCoV, higher ACE2 expression might also lead to higher risk of SARSCoV2 infection.

[1]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[2]  C. Eastin,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.

[3]  D. Diz,et al.  Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 , 2005, Circulation.

[4]  D. Averill,et al.  Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors , 2004, Hypertension.

[5]  N. Alenina,et al.  The ACE2/Angiotensin-(1–7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1–7) , 2017, Physiological reviews.

[6]  Jing Yuan,et al.  Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury , 2020, Science China Life Sciences.

[7]  Akram Khan,et al.  A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome , 2017, Critical Care.

[8]  I. Hochberg,et al.  Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. , 2005, American journal of physiology. Heart and circulatory physiology.

[9]  G. Fey,et al.  Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor , 2004, Biochemical and Biophysical Research Communications.

[10]  Shi Hu,et al.  Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig , 2020, bioRxiv.

[11]  J. Penninger,et al.  SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS , 2009, European journal of clinical investigation.

[12]  Haibo Zhang,et al.  Recombinant human ACE2: acing out angiotensin II in ARDS therapy , 2017, Critical Care.

[13]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[14]  Qun Li.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020 .

[15]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[16]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[17]  L. Poon,et al.  Initial viral load and the outcomes of SARS , 2004, Canadian Medical Association Journal.

[18]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[19]  T. van der Poll,et al.  Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study , 2019, Annals of Intensive Care.

[20]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.